See more : Shindaeyang Paper Co., Ltd. (016590.KS) Income Statement Analysis – Financial Results
Complete financial analysis of PPD, Inc. (PPD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PPD, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Avacta Group Plc (AVCTF) Income Statement Analysis – Financial Results
- ShenZhen Properties & Resources Development (Group) Ltd. (000011.SZ) Income Statement Analysis – Financial Results
- Grenergy Renovables, S.A. (GRE.MC) Income Statement Analysis – Financial Results
- Chin Hsin Environ Engineering Co., Ltd. (6951.TW) Income Statement Analysis – Financial Results
- BlackRock MuniYield California Quality Fund, Inc. (MCA) Income Statement Analysis – Financial Results
PPD, Inc. (PPD)
About PPD, Inc.
PPD, Inc. provides drug development services to the biopharmaceutical industry worldwide. The company operates through Clinical Development Services and Laboratory Services segments. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri- and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company was founded in 1985 and is headquartered in Wilmington, North Carolina.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|
| Revenue | 4.68B | 4.03B | 3.75B | 3.00B | 2.68B |
| Cost of Revenue | 2.88B | 2.41B | 2.27B | 1.54B | 1.39B |
| Gross Profit | 1.80B | 1.62B | 1.47B | 1.46B | 1.29B |
| Gross Profit Ratio | 38.42% | 40.24% | 39.32% | 48.80% | 48.25% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 1.29B | 1.20B | 1.07B | 1.20B | 978.63M |
| Operating Expenses | 1.29B | 1.20B | 1.07B | 1.20B | 978.63M |
| Cost & Expenses | 4.17B | 3.61B | 3.35B | 2.74B | 2.37B |
| Interest Income | 0.00 | 0.00 | 5.45M | 3.55M | 2.51M |
| Interest Expense | 216.93M | 311.74M | 263.62M | 253.89M | 203.29M |
| Depreciation & Amortization | 279.12M | 264.83M | 258.97M | 279.07M | 260.49M |
| EBITDA | 668.54M | 627.35M | 666.36M | 544.62M | 630.92M |
| EBITDA Ratio | 14.28% | 15.56% | 17.77% | 18.15% | 23.55% |
| Operating Income | 509.43M | 418.49M | 402.24M | 261.33M | 314.26M |
| Operating Income Ratio | 10.88% | 10.38% | 10.73% | 8.71% | 11.73% |
| Total Other Income/Expenses | -321.88M | -359.21M | -255.61M | -244.86M | -147.37M |
| Income Before Tax | 187.55M | 59.28M | 146.63M | 16.47M | 166.89M |
| Income Before Tax Ratio | 4.01% | 1.47% | 3.91% | 0.55% | 6.23% |
| Income Tax Expense | 18.81M | 2.96M | 39.58M | -284.36M | -15.96M |
| Net Income | 153.69M | 47.82M | 104.19M | 296.03M | 183.10M |
| Net Income Ratio | 3.28% | 1.19% | 2.78% | 9.86% | 6.83% |
| EPS | 0.44 | 0.14 | 0.32 | 0.91 | 0.56 |
| EPS Diluted | 0.44 | 0.14 | 0.32 | 0.91 | 0.56 |
| Weighted Avg Shares Out | 346.68M | 339.43M | 324.30M | 325.04M | 324.22M |
| Weighted Avg Shares Out (Dil) | 346.68M | 339.43M | 324.30M | 325.86M | 324.30M |
PPD Announces Fourth Quarter and Full-Year 2020 Earnings Conference Call
WILMINGTON, N.C.--(BUSINESS WIRE)--PPD, Inc. (Nasdaq: PPD), a leading global contract research organization, will host a conference call on Wednesday, Feb. 24, 2021, at 9 a.m. (U.S. Eastern Time) to discuss its fourth quarter and full-year 2020 financial results. Investors and...
PPD Announces Fourth Quarter and Full-Year 2020 Earnings Conference Call
WILMINGTON, N.C.--(BUSINESS WIRE)--PPD, Inc. (Nasdaq: PPD), a leading global contract research organization, will host a conference call on Wednesday, Feb. 24, 2021, at 9 a.m. (U.S. Eastern Time) to discuss its fourth quarter and full-year 2020 financial results. Investors and...
PPD to Present at the 39th Annual J.P. Morgan Healthcare Conference
WILMINGTON, N.C.--(BUSINESS WIRE)--PPD, Inc. (Nasdaq: PPD), a leading global contract research organization, will present virtually at the 39th Annual J.P. Morgan Healthcare Conference. David Simmons, chairman and CEO, and Chris Scully, CFO, are scheduled to present on Monday, Jan. 11,...
Why PPD, Inc. (PPD) Might be Well Poised for a Surge
PPD, Inc. (PPD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
PPD百时益 公司荣获2020年度“大中华区最佳职场TM”称号
北卡罗来纳州威明顿--(BUSINESS WIRE)--(美国商业资讯)--PPD, Inc.（纳斯达克代码：PPD）被 Great Place to Work® （卓越职场®）评为 Best Workplaces in Greater China™（大中华区最佳职场™）之一，Great Place to Work® （卓越职场®）是一家关注高信任、高绩效职场文化的全球权威机构，为企业、非盈利组织和政府机构提供执行咨询和文化咨询服务。在获此殊荣的同时，PPD 宣布在中国采用新的中文公司名称，以体现其在中国的持续发展。 PPD 在亚太地区拥有超过 20 年的本地运营经验，包括在大中华区拥有广泛的药物开发和研究能力，公司的临床业务遍及全国，覆盖中国大部分区域和人口。 PPD 副总裁兼中国区业务总经理 丁鸣博士表示：“这项荣誉的获得证实了PPD 是当之无愧的大中华区“最佳职场”之一。公司的企业文化为员工提供了开放的环境，促使员工不断成长，并为客户提供高质量且高效的服务。自 2019 年以来，我们在大中华区的员工数量增加了一倍多，目前有大约 1,100 位员工并保持极高的留任率。我们敬业的员工为客户提供了卓越的药物开发工作连续性并培养了高度稳定的客户忠诚度。” Great Place to Work （卓越职场）根据员工对调查问卷的回答评估企业文化，主要从五个维度进行分析：尊重、友爱、信赖、自豪和公平，并通过全面的评估确定企业政策计划的预期成效与其实际成效之间的差距，更好地识别出成为“卓越职场”的成功因素，以便更有效地创建出色的职场文化。2020 年，大中华区只有 38 家公司凭借堪称典范的职场环境而获此殊荣。 今年年初，PPD 公司宣布将扩大其在中国的运营规模和领导团队，并将在苏州开设一个全新的多功能临床研究实验室，为国际和中国医药公司提供更完善的临床开发、实验室、法规监管、研究中心管理、患者获取和审批后服务。占地...
PPD百時益 公司榮獲2020年度“大中華區最佳職場TM”稱號
北卡羅來納州威明頓--(BUSINESS WIRE)--(美國商業資訊)--PPD, Inc.（納斯達克代碼：PPD）被Great Place to Work® （卓越職場®）評為Best Workplaces in Greater China™（大中華區最佳職場™）之一，Great Place to Work® （卓越職場®）是一家關注高信任、高績效職場文化的全球權威機構，為企業、非盈利組織和政府機構提供執行諮詢和文化諮詢服務。在獲此殊榮的同時，PPD 宣佈在中國大陸採用新的中文公司名稱，以體現其在中國的持續發展。 PPD 在亞太地區擁有超過 20 年的本地運營經驗，包括在大中華區擁有廣泛的藥物開發和研究能力，公司的臨床業務遍及全國，覆蓋中國大部分區域和人口。 PPD 副總裁兼中國區業務總經理丁鳴博士表示：“這項榮譽的獲得證實了PPD 是當之無愧的大中華區“最佳職場”之一。公司的企業文化為員工提供了開放的環境，促使員工不斷成長，並為客戶提供高質量且高效的服務。自2019 年以來，我們在大中華區的員工數量增加了一倍多，目前有大約1,100 位員工並保持極高的留任率。我們敬業的員工為客戶提供了卓越的藥物開發工作連續性並培養了高度穩定的客戶忠誠度。” Great Place to Work （卓越職場）根據員工對調查問卷的回答評估企業文化，主要從五個維度進行分析：尊重、友愛、信賴、自豪和公平，並通過全面的評估確定企業政策計劃的預期成效與其實際成效之間的差距，更好地識別出成為“卓越職場”的成功因素，以便更有效地創建出色的職場文化。 2020 年，大中華區只有 38 家公司憑藉堪稱典範的職場環境而獲此殊榮。 今年年初，PPD 公司宣布將擴大其在中國的運營規模和領導團隊，並將在蘇州開設一個全新的多功能臨床研究實驗室，為國際和中國醫藥公司提供更完善的臨床開發、實驗室、法規監管、研究中心管理、患者獲取和審批後服務。佔地 67,000 平方英尺（6,224 平方米）的蘇州多功能實驗室預計將於 2021...
PPD Recognized as a Best Place to Work in Greater China
WILMINGTON, N.C.--(BUSINESS WIRE)--PPD, Inc. (Nasdaq:PPD) has been named one of the Best Workplaces in Greater China™ by Great Place to Work®, a global authority on high-trust, high-performance workplace cultures that provides executive advisory and culture consulting services to businesses, nonprofits...
Buy And Hold The Top 10 IPOs Of 2020 For Long-Term Gains
The year has seen more than 370 companies go public, so finding the 10 best IPOs to invest in won't be easy. Here are the top contenders.
5 Stocks Set to Score From MSCI Index Rebalancing
Most experienced investors are well aware of the major indexes that compose the equity markets.
PPD Named Clinical Research Company of the Year
WILMINGTON, N.C.--(BUSINESS WIRE)--PPD, Inc. (Nasdaq:PPD), was named the Clinical Research Company of the Year for winning multiple awards at the PharmaTimes Clinical Researcher of the Year competitions. In addition to PPD winning the highest honor at the PharmaTimes International Clinical...
Source: https://incomestatements.info
Category: Stock Reports